These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27665573)

  • 1. Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
    Green B; Crauwels H; Kakuda TN; Vanveggel S; Brochot A
    Clin Pharmacokinet; 2017 May; 56(5):525-536. PubMed ID: 27665573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
    Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
    Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
    Lubomirov R; Arab-Alameddine M; Rotger M; Fayet-Mello A; Martinez R; Guidi M; di Iulio J; Cavassini M; Günthard HF; Furrer H; Marzolini C; Bernasconi E; Calmy A; Buclin T; Decosterd LA; Csajka C; Telenti A;
    Pharmacogenet Genomics; 2013 Jan; 23(1):9-18. PubMed ID: 23111422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.
    Kakuda TN; Brochot A; Green B; Nijs S; Vis P; Opsomer M; Tomaka FL; Hoetelmans RM
    J Clin Pharmacol; 2016 Nov; 56(11):1395-1405. PubMed ID: 27060341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review.
    Havens JP; Podany AT; Scarsi KK; Fletcher CV
    Clin Pharmacokinet; 2020 Feb; 59(2):137-154. PubMed ID: 31679131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
    Kakuda TN; Wade JR; Snoeck E; Vis P; Schöller-Gyüre M; Peeters MP; Corbett C; Nijs S; Vingerhoets J; Leopold L; De Smedt G; Woodfall BJ; Hoetelmans RM
    Clin Pharmacol Ther; 2010 Nov; 88(5):695-703. PubMed ID: 20881958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Etravirine drug interactions].
    Pérez VE; Sánchez-Parra C; Serrano Villar S
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():27-31. PubMed ID: 20116625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
    Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Fletcher CV; Acosta EP;
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):294-296. PubMed ID: 27103489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
    Aouri M; Barcelo C; Guidi M; Rotger M; Cavassini M; Hizrel C; Buclin T; Decosterd LA; Csajka C;
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
    Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
    Clin Pharmacokinet; 2011 Jan; 50(1):25-39. PubMed ID: 21142266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.
    Ramanathan S; Kakuda TN; Mack R; West S; Kearney BP
    Antivir Ther; 2008; 13(8):1011-7. PubMed ID: 19195326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
    Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.